STK11 and non-small cell lung carcinoma: Ongoing scientific efforts are seeking to decipher the mechanistic basis for this lack of ICI response in STK11/LKB1 co-mutated tumors with the aim of developing new strategies to turn “cold” tumors into “hot” ones and thus increase the benefit of immune checkpoint blockade for NSCLC patients with this prevalent genotype [102].